Ribavirin disposition in high‐risk patients for acquired immunodeficiency syndrome

Ribavirin is a broad‐spectrum antiviral drug that has in vitro activity against human immunodeficiency virus. To determine the kinetics of ribavirin, 17 symptom‐free homosexual men with lymphadenopathy were studied. Single doses of ribavirin, 600, 1200, or 2400 mg, were given orally or intravenously. The plasma ribavirin concentration‐time profiles were well fitted by a three‐compartment open model. Ribavirin followed linear kinetics over the dose range studied. The mean 1‐hour postinfusion concentrations after intravenous ribavirin, 600, 1200, and 2400 mg, were 8.0, 19.7, and 37.1 μmol/L, respectively. The mean ± SD plasma β‐phase half‐life, terminal‐phase (γ) half‐life, and volume of distribution at steady state were 2.0 ± 1.1 hours, 35.5 ± 14.0 hours, and 647 ± 258 L, respectively. The mean ribavirin renal clearance and total body clearance were 99 ± 30 and 283 ± 37 ml/min, respectively. After an oral dose of 600,1200, and 2400 mg, the mean peak plasma ribavirin concentrations (which occurred 1.5 hours after administration) were 5.1, 9.9, and 12.6 μmol/L, respectively. The mean absorption half‐life and bioavailability of ribavirin were 0.5 hour and 45%. Ribavirin had no plasma protein binding and the drug accumulated within red blood cells. In conclusion, ribavirin is incompletely absorbed from the gastrointestinal tract, its renal excretion accounts for approximately one third of the drug's elimination, and drug accumulation (>threefold) will result with repetitive dosing at the 6‐ to 8‐hour dosing interval currently used. Clinical Pharmacology and Therapeutics (1987) 41, 546–555; doi: 10.1038/clpt.1987.70